Delcath Systems, Inc

Canaccord Genuity Acted as a Joint Bookrunner in a Follow-On Offering for Delcath Systems, Inc.

Delcath Systems, Inc. (the “Company”) (Nasdaq:DCTH), priced its $19.3 million upsized public offering on December 8, 2020 at a price of $13.25 per share. The Company issued 1,460,027 shares of common stock. The Underwriters exercised their option to purchase an additional $219,004 shares of common stock at a public offering price, bringing the total proceeds to $22.2 million, less the underwriting discounts and commissions.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Canaccord Genuity acted as a joint placement agent to the Company. The Canaccord Genuity team included Eugene Rozelman, Jennifer Pardi, Tara Hartigan, Brian O’Connor, Mike Wright, Gaurav Mehta, Tyler Chamberland, Brooke Szczygiel, and Anusha Kavuru.